Bibliografia UJ CM



Zapytanie: RUSSEL-SZYMCZYK M
Liczba odnalezionych rekordów: 6



Przejście do opcji zmiany formatu | Wyświetl/ukryj etykiety | Wersja do druku | | | Nowe wyszukiwanie
1/6
P[aweł] Kawalec, P. Holko, M. Boratynska, M. Glyda, E[wa] Ignacak, M. Russel-Szymczyk, M. Szkultecka-Sebek, A. Kaweczynska-Lason.
Cost-effectiveness and cost-utility analysis of 200 days prophylaxis of cytomegalovirus (CMV) infections in high risk (D+/R-) kidney transplant recipients in Poland.
Value in Health
2011 : Vol. 14, nr 7, s. A280-A281
ISPOR 14th Annual European Congress, Madrid, Spain, November 5-8, 2011.
SZZ
SIF
2/6
P[aweł] Kawalec, P. Badurak, T. Denisso, D. Jastrzebski, M. Marek, A. Pluzanski, A. Szczesna, M. Szkultecka-Debek, M. Russel-Szymczyk.
Bevacizumab + paclitaxel + carboplatin (Bev + Pac + Car) vs. pemetrexed + cisplatin (Pem + Cis) in adenocarcinoma non-squamous non-small Cell Lung Cancer (NSCLC): a cost-effectiveness analysis from a Polish public payer's perspective.
Value in Health
2010 : Vol. 13, nr 7, s. A268
ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
SZZ
SIF
3/6
R. Oleszko, P[aweł] Kawalec, A. Drobniak, R. Stec, J[oanna] Streb, M. Russel-Szymczyk, M. Szkultecka-Debek.
Budget impact analysis of capecitabine in adjuvant treatment of patients with resected Dukes' c colon cancer (cc) from Polish public payer's and patient's perspectives.
Value in Health
2010 : Vol. 13, nr 7, s. A257
ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
SZZ
SIF
4/6
P[aweł] Kawalec, E. Stawowczyk, M. Russel-Szymczyk, M. Szkultecka-Debek, R. Aultman, E. Carr, E[wa] Lech-Maranda, A. Krawcewicz, M. Wach, G. Mazur.
An economic evaluation of rituximab versus other first-line treatments for patients with Chronic Lymphocytic Leukemia in Poland.
Value in Health
2009 : Vol. 12, nr 7, s. A273, abstr. PCN88
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
5/6
P[aweł] Kawalec, J[acek] Kuzma, M. Szkultecka-Debek, M. Russel-Szymczyk, A. Slizien-Debska, J. Malyszko, M. Durlik.
Cost-minimization analysis: Mircera (methoxy polyethylene glycol-epoetin beta) vs. Aranesp (darbepoetin alfa) in patients with chronic kidney disease (ckd) who are not receiving haemodialysis, in Polish setting.
Value in Health
2009 : Vol. 12, nr 7, s. A310
ISPOR Twelfth Annual European Congress, Paris, France, October 24-27, 2009.
SZZ
SIF
6/6
P[aweł] Kawalec, A. Szawlowski, I. Federowicz, M[onika] Szkultecka-Debek, M. Russel-Szymczyk.
Cost minimization analysis of advanced gastric cancer treatment with capecitabine/cispatine (XP) vs. 5-FU/cispatin (FP) regiments.
Value in Health
2008 : Vol. 11, nr 6, s. A473, abstr. PCN44
ISPOR Eleventh Annual European Congress, Athens, Greece, November 8-11, 2008.
SZZ
SIF
  Wyświetl ponownie stosując format:
Wyświetl/ukryj etykiety | Wyświetlenie wyników w wersji do druku | Pobranie pliku do edytora | Nowe wyszukiwanie | Biblioteka Medyczna UJ